
1. j antimicrob chemother. 2013 mar;68(3):690-6. doi: 10.1093/jac/dks455. epub 2012 
nov 14.

role evolution viral tropism patients advanced hiv disease
receiving intensified initial regimen anrs 130 apollo trial.

charpentier c(1), joly v, larrouy l, fagard c, visseaux b, de verdière nc, raffi 
f, yeni p, descamps d; anrs 130 apollo trial study group.

collaborators: aumaître h, medus m, neuville s, saada m, abgrall s, bentata m,
bouchaud o, cailhol j, cordel h, dhote r, gros h, honoré-berlureau p, huynh t,
krivitzky a, mansouri r, poupard m, prendki v, radia d, rouges f, touam f, warde 
b, de castro n, colin de verdière n, delgado j, ferret s, gallien s, kandel t,
lafaurie m, lagrange m, lascoux-combe c, le d, molina jm, pavie j, pintado c,
ponscarme d, rachline a, rozenbaum w, sereni d, taulera o, estavoyer jm, faucher 
jf, foltzer a, hoen b, hustache-mathieu l, dupon m, dutronc h, neau d, ragnaud
jm, raymond i, boucly s, lortholary o, viard jp, bechara c, delfraissy jf, ghosn 
j, goujard c, kamouh w, môle m, quertainmont y, bergmann jf, boulanger e,
castillo h, parrinello m, rami a, sellier p, lepeu g, pichancourt g, bernard l,
berthé h, clarissou j, gory m, melchior jc, perronne c, stegman s, de truchis p, 
derradji o, malet m, teicher e, vittecoq d, chakvetadze c, fontaine c, lukiana t,
pialloux g, slama l, bonnet d, boucherit s, el alami talbi n, fournier i, gervais
a, joly v, iordache l, laurichesse jj, leport c, pahlavan g, phung bc, yeni p,
bennamar n, brunet a, guillevin l, salmon-ceron d, tahi t, chesnel c, dominguez
s, jouve p, lelièvre jd, levy y, melica g, sobel a, ben abdallah s, bonmarchand
m, bricaire f, herson s, iguertsira m, katlama c, kouadio h, schneider l, simon
a, valantin ma, abel s, beaujolais v, cabié a, liauthaud b, pierre françois s,
abgueguen p, chennebault jm, loison j, pichard e, rabier v, delaune j, louis i,
morlat p, pertusa mc, brunel-delmas f, chiarello p, jeanblanc f, jourdain jj,
livrozet jm, makhloufi d, touraine jl, augustin-normand c, bailly f, benmakhlouf 
n, brochier c, cotte l, gueripel v, koffi k, lack p, lebouché b, maynard m,
miailhes p, radenne s, schlienger i, thoirain v, trepo c, drogoul mp, fabre g,
faucher o, frixon-marin v, gastaut ja, peyrouse e, poizot-martin i, jacquet jm,
le facher g, merle de boever c, reynes j, tramoni c, allavena c, billaud e, biron
c, bonnet b, bouchez s, boutoille d, brunet-françois c, hüe h, mounoury o, raffi 
f, reliquet v, aubry o, esnault jl, leautez-nainville s, perré p, suaud i, bréaud
s, ceppi c, dellamonica p, de salvador f, durant j, ferrando s, fuzibet jg,
leplatois a, mondain v, perbost i, pugliese p, rahelinirina v, rosenthal e,
sanderson f, vassalo m, arvieux c, chapplain jm, michelet c, ratajczak m, revest 
m, souala f, tattevin p, chéneau c, fischer p, lang jm, partisani m, rey d,
bastides f, besnier jm, le bret p, choutet p, dailloux jf, guadagnin p, nau p,
rivalain j, soufflet a, aïssi e, melliez h, pavel s, mouton y, yazdanpanah y,
boyer l, burty c, letranchant l, may t, wassoumbou s, blum l, danne o, arthus ma,
dion p, certain a, tabuteau s, beuscart a, agher n, frosch a, couffin-cadiergues 
s, diallo a.

author information: 
(1)laboratoire de virologie, assistance publique-hôpitaux de paris (ap-hp),
groupe hospitalier bichat-claude bernard, hupnvs, université paris diderot, paris
7, pres sorbonne paris cité, ea4409, 75018, paris, france.

objectives: aims study assess patients advanced hiv
disease receiving antiretroviral therapy (art) intensification enfuvirtide
(i) resistance virological failure (vf), (ii) impact baseline tropism on
immunovirological response, (iii) hiv-1 dna tropism evolution art.
methods: anrs 130 apollo randomized trial evaluated naive patients the
immunovirological impact standard art without (control arm) with
enfuvirtide. tropism determined rna dna v3-loop sequencing
interpreted using geno2pheno algorithm.
results: baseline median cd4 cell count 30 cells/mm(3). among 170 
patients assessable virological substudy, hiv-1 rna tropism as
follows: 60% viruses r5 40% r5x4/x4. hiv-1 dna tropism as
follows: 54% r5 46% r5x4/x4. week 24, 39% 49% patients
experienced vf enfuvirtide control arms, respectively. the
enfuvirtide arm, resistance-associated mutations enfuvirtide were
detected. control arm, two patients displayed drug-resistant viruses at
the time vf. impact baseline tropism observed immunovirological
response, regardless study arm. among 25 patients experiencing dna
tropism switch baseline week 24, 16 (64%) switched r5 to
r5x4/x4. latter mostly successfully suppressed patients receiving
enfuvirtide exhibiting poorer immunological response.
conclusions: baseline rna tropism impact immunovirological
response. drug resistance mutations detected fusion inhibitor. 
finally, mechanism replenishment viral cellular reservoir x4
viruses observed needs analysed.

doi: 10.1093/jac/dks455 
pmid: 23152480  [indexed medline]

